Asymmetric dimethylarginine in end-stage renal disease patients: A biomarker modifiable by calcium blockade and angiotensin II antagonism?

Kidney International

Volumn 70, Issue 12, 2006, Pages 2053-2055

  Zoccali, C ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TELMISARTAN; VALSARTAN;

BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 33845331757     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001898     Document Type: Note

References (9)

1. Mallamaci F, Tripepi G, Cutrupi S et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337.
2. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
3. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202.
4. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611-619.
5. Kielstein JT, Donnerstag F, Gasper S et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-2029.
6. Boger RH, Schwedhelm E, Maas R et al. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc Med 2005; 10(Suppl 1): S97-S102.
7. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int 2006; 70: 2109-2115.
8. Osanai T, Saitoh M, Sasaki S et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42: 985-990.
9. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006; 48: 73-79.